...
首页> 外文期刊>Current pharmaceutical design >Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
【24h】

Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis

机译:基于细胞的耐受性疗法,多发性硬化症的动物模型的经验,1型糖尿病和类风湿性关节炎

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
机译:基于细胞的耐受性疗法是一种治疗自身免疫疾病和移植排斥的有希望的方法。 在治疗疾病实验模型中的各种自身免疫疾病中,特别探索了调节性T细胞和耐耐耐受性树突细胞。 虽然这些细胞中的一些已经在有限数量的临床试验中进行了测试,但仍然需要对自身免疫动物模型中的耐受性细胞进行临床前研究。 本综述将重点关注从实验动物模型中获得的数据的相关性,用于使用耐含耐受性细胞的疗法。 此外,还将讨论进一步改善耐受性细胞的透视措施朝向增强抑制活性和细胞的稳定性的透视程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号